by Amruth Sundarkumar | Nov 30, 2022 | China, High Yield Bonds
Fosun Pharma is planning a sale of Indian drugmaker Gland Pharma at a market value of $3.8bn after receiving interest from potential suitors, as per Bloomberg sources. Gland Pharma specializes in injectable drugs like antibiotics, oncology and cardiology treatments...
by Amruth Sundarkumar | Nov 24, 2022 | China, High Yield Bonds
Chinese conglomerate Fosun International is said to be planning to sell a minority stake in Alibaba’s logistics arm Cainiao for up to $1bn, as per sources. Fosun plans to sell a less than 5% stake in Cainiao and the plan is only in early stages, they said....
by Amruth Sundarkumar | Nov 15, 2022 | China, High Yield Bonds
Fosun International is said to be exploring options to sell several assets in China and abroad as per sources. It is said that Fosun’s domestic food and beverage business, including noodle chain Songhelou is available for potential investors/buyers. Also, a...
by Amruth Sundarkumar | Oct 28, 2022 | China, High Yield Bonds
Fosun International is said to be seeking strategic options that include selling either a majority or minority stake in reinsurer Peak Reinsurance in order to pay its debts. Sources said that the transaction which is at early stages, could value Peak Re at...
by Amruth Sundarkumar | Oct 26, 2022 | China, Credit Ratings, High Yield Bonds
Fosun International and its senior unsecured notes were downgraded to B2 from B1 by Moody’s. The rating agency said that the downgrade was due to Fosun’s weak liquidity, the recent rapid decline in the market value of its listed assets and the execution...
